Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL)
April 12, 2016 – The American Food and Drug Administration (FDA) just approved Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a …